Hepatitis E virus is a major cause of epidemic hepatitis, often leads to large-scale outbreak. The symptom is similar to Hepatitis A, but with higher mortality. The mortality in pregnant women is 15-25%. According to WHO, 1/3 of the world’s population were infected with hepatitis E virus. In South and East Asia, there would be 650 million cases every year. It would cause 160,000 deaths and 2700 abortions every year. From 1986 to 1988, there was an outbreak in Xin Jiang Province. The total case number is about 120,000. Caused nearly a thousand deaths. And the incidence of hepatitis E is increasing every year in China.
NIDVD worked with Xiamen Innovax Biotech, developed Recombinant Hepatitis E Vaccine, Hecolin. It is the first HEV vaccine goes into production. The project started in 1998, and phase III clinical study was finished in 2009. The test data of phase III was published on The Lancet in 2010. In 2011, it is approved by China's State Food and Drug Administration (SFDA) and then put in production. With the lead of Professor Xia Ningshao, the whole team worked for years to make such great achievement. The vaccine has independent intellectual property rights, it is a milestone of national scientific innovation. And it is a great contribution to global hepatitis prevention.